Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1993-5-24
|
pubmed:abstractText |
The overall cure rate of patients with metastatic non-seminoma of the testis is high and a recent survey of 795 patients by the Medical Research Council indicated that 85% were alive 3 years after the start of chemotherapy. Two major categories of patients can be identified with a poorer prognosis. First are those with adverse prognostic factors at presentation defined by presence of one of the following factors: high tumour markers, more than 20 lung metastases, liver bone or brain metastases, mediastinal mass more than 5 cm. In these patients, the RMH is investigating accelerated chemotherapy employing a 7 day cycle, combined carboplatin and cisplatin and infusional bleomycin (C-BOP regimen). Of 21 patients followed for a median of 18 months, 18 (85%) have remained continuously disease free. The second adverse group are patients who have already failed first line chemotherapy. A multivariate prognostic factor analysis on 105 patients treated at the Royal Marsden Hospital indicates that adverse factors for salvage chemotherapy are the disease-free interval and the extent of disease at relapse. Our approach to patients with disseminated relapse includes high dose carboplatin and etoposide with autologous bone marrow support. With follow-up from 3-24 months, 7 of 11 patients treated with high dose chemotherapy remain continuously free from progressive disease. The need for an alkylating agent in the high dose combination is questionable.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0302-2838
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
219-22
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8386653-Analysis of Variance,
pubmed-meshheading:8386653-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8386653-Bone Marrow Transplantation,
pubmed-meshheading:8386653-Combined Modality Therapy,
pubmed-meshheading:8386653-Follow-Up Studies,
pubmed-meshheading:8386653-Humans,
pubmed-meshheading:8386653-Male,
pubmed-meshheading:8386653-Neoplasms, Germ Cell and Embryonal,
pubmed-meshheading:8386653-Prognosis,
pubmed-meshheading:8386653-Salvage Therapy,
pubmed-meshheading:8386653-Survival Rate,
pubmed-meshheading:8386653-Testicular Neoplasms
|
pubmed:year |
1993
|
pubmed:articleTitle |
Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma.
|
pubmed:affiliation |
Department of Radiotherapy and Oncology, Royal Marsden Hospital, Sutton, UK.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|